Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Absci Corporation (Nasdaq: ABSI) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical and biotechnology company using generative AI and synthetic biology to design biologic therapeutics, Absci uses these filings to report on its financial condition, pipeline progress, capital markets activity, and key corporate events.
Investors can review Absci’s current reports on Form 8-K, which have recently covered topics such as quarterly financial results, updates on internal programs like ABS-201 and ABS-101, investor presentations, and material definitive agreements including underwritten equity offerings. These filings also confirm that Absci’s common stock is listed on The Nasdaq Global Select Market under the symbol ABSI.
In addition to 8-Ks, users can locate Absci’s annual reports on Form 10-K and quarterly reports on Form 10-Q through this page. Those reports typically include management’s discussion and analysis, audited or reviewed financial statements, and detailed information on the company’s Integrated Drug Creation platform, clinical-stage programs, risk factors, and liquidity. For a company like Absci, these periodic reports are central to understanding how it funds and advances its AI-designed antibody pipeline and partnered drug creation projects.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as changes in cash runway, updates to clinical development plans, or new collaboration agreements. Real-time updates from the SEC’s EDGAR system ensure that new Absci filings appear promptly, while access to insider transaction reports on Form 4, when filed, can help users monitor equity awards and trades by directors and officers.
By using this page, investors and researchers can efficiently navigate Absci’s regulatory history, compare successive filings, and place news releases about its generative AI platform and clinical programs in the context of the company’s formal SEC disclosures.
Absci Corporation reported third‑quarter 2025 results. Partner program revenue was $0.378 million, down from $1.701 million a year ago, reflecting milestone timing and program mix. The company posted a net loss of $28.7 million (basic and diluted loss per share $0.20) on total operating expenses of $30.5 million, including $19.2 million in R&D. For the first nine months, revenue was $2.15 million and net loss was $85.6 million.
Liquidity remained solid with $152.5 million in cash, cash equivalents and marketable securities as of September 30, 2025. The company strengthened its balance sheet in 2025 through a $20.0 million PIPE with AMD, a July offering yielding $46.7 million in net proceeds, and $35.7 million via a prior ATM program. Shares outstanding were 150,371,531 as of October 31, 2025.
Program updates: ABS‑101 Phase 1 in healthy volunteers showed extended half‑life versus first‑generation anti‑TL1A programs with a favorable safety profile; Absci plans to seek a partner after trial completion. ABS‑201 received HREC approval in Australia, with first dosing targeted for December 2025. A subsequent event settled Totient contingent consideration for approximately $7.6 million and released $8.7 million from escrow.
Absci Corporation announced its financial results for the third quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 under Item 2.02, and noted that this information is being furnished and not deemed filed under the Exchange Act.
Absci also filed a Fall 2025 corporate presentation as Exhibit 99.2, which includes internal pipeline program updates and is available in the News & Events section of its website.
Absci Corporation entered into a Letter Agreement with SBGH, LLC that amends the 2021 Totient merger terms and sets a final distribution of milestone consideration. The agreement provides that certain former Totient stockholders will receive approximately $7.6 million, and Absci will receive approximately $8.7 million, in full satisfaction of all potential milestone payments under the merger agreement.
The Letter Agreement, dated October 31, 2025, is filed as an exhibit, with certain portions redacted as immaterial and confidential.
Absci (ABSI) CEO and Director reported a routine tax withholding on restricted stock unit vesting. On 10/14/2025, 23,293 shares of common stock were withheld at $3.68 per share under transaction code F, which reflects shares withheld to satisfy taxes and not an open-market trade.
Following this event, the reporting person beneficially owned 8,361,328 shares directly. An additional 2,269,987 shares are held by Brittany McClain and are subject to a voting agreement and proxy that entitles the reporting person to vote those shares.
Absci (ABSI) reported an insider transaction on Form 4. The company’s CFO/CBO recorded a Code F transaction on 10/14/2025, reflecting 387 shares of common stock withheld by the issuer at $3.68 to satisfy taxes upon RSU vesting. Following this withholding, the reporting person directly owns 409,354 shares. The filing notes this was for tax withholding and not a discretionary trade.
Absci (ABSI) reported an insider Form 4 for its Chief Innovation Officer detailing tax withholding related to RSU vesting. On 10/14/2025, 3,092 shares of common stock were withheld under transaction code F at $3.68 to satisfy taxes, which the footnote clarifies was not a discretionary trade. Following this administrative transaction, the officer directly beneficially owns 324,172 shares.
Absci (ABSI) disclosed a Form 4 for a company officer (SVP, CAO). On 10/14/2025, 21,950 shares of common stock were withheld under code “F” to cover tax obligations upon the vesting of restricted stock units. The withholding price was $3.68 per share. After this transaction, the officer directly holds 161,283 shares. The filing states the withholding was for taxes related to RSU vesting and was not a discretionary trade.
Menelas N. Pangalos, a director of Absci Corp (ABSI), reported an open-market purchase of 95,785 shares of Absci common stock on 09/22/2025 at a price of $2.66 per share. After the transaction, Mr. Pangalos beneficially owned 113,960 shares. The filing states the purchase was made in accordance with the issuer's trading policies. The Form 4 was executed by Shelby Walker as attorney-in-fact on 09/22/2025.
Insider purchase by Absci Corp officer: Todd Bedrick, listed as SVP and CAO, reported an open-market purchase of 10,000 shares of Absci Corp (ABSI) on 09/22/2025 at a reported price of $2.70 per share. Following the transaction he beneficially owned 180,428 shares, held in a direct capacity. The Form 4 was signed by an attorney-in-fact on his behalf and notes the purchase was made in accordance with the issuer's trading policies.
Absci Corporation insider report: This Form 4 shows that Zachariah Jonasson, an officer serving as CFO/CBO, had 8,319 shares of Absci common stock withheld on 08/31/2025 to satisfy tax withholding related to the vesting and settlement of restricted stock units. The shares were withheld at a reported price of $2.39 per share. After the withholding, Mr. Jonasson is reported to beneficially own 409,741 shares of Absci common stock as a direct holder. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/02/2025.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
